Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: Osseodensification Versus Osteotome Internal Sinus Lifting in Delayed Implant Placement Primary completion pushed from Mar 21, 2027 to Aug 21, 2027 Ain Shams UniversityNot applicable NCT05495490
  2. Minor: Treating New Learning and Memory Deficits Following Stroke Primary and study completion pushed from Oct 2026 to Dec 2026 Kessler FoundationNot applicable NCT07127367
  3. Minor: Case Management Dyad Primary completion pushed from Sep 30, 2026 to Nov 30, 2026 University of ChicagoNot applicable NCT06162897
  4. Minor: Tap Trust Intervention on Water Security Experiences and Beverage Intake Primary completion pushed from Jul 2027 to Sep 30, 2027 Stanford UniversityNot applicable NCT07197216
  5. Minor: Acoustic Stimulation During Sleep: Effects on Memory and p-tau217 in MCI Primary completion pushed from Sep 2027 to Dec 2027 Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida)Not applicable NCT07529015
  6. Minor: Changes in Perioperative Blood Volume and Fluid Distribution in Patients Undergoing Primary Total Hip Replacement Primary and study completion pushed from Sep 2026 to Dec 2026 Copenhagen University Hospital, HvidovreNot specified NCT06888908
  7. Minor: Symptoms, Respiratory Dysfunction and Frailty Level in Allergic and Eosonophilic Asthmatics Primary completion pushed from Oct 30, 2026 to Mar 30, 2027 Hacettepe UniversityNot specified NCT06796894
  8. Minor: Diabetes Prevention by Group Intervention and CGM Use in Pre-diabetic Adults Primary completion pushed from Nov 2026 to Mar 2027 Sam Houston State UniversityNot applicable NCT07543068
  9. Minor: Using EMA Data to Inform a Web-intervention for Couples Concerned About Drinking Primary completion pushed from Aug 2026 to Dec 2026 Stanford UniversityNot applicable NCT06501677
  10. Minor: High-Flow Tracheal Therapy on Tracheobronchial Secretions in Tracheostomized Patients Primary completion pushed from Aug 1, 2027 to Jan 1, 2028 Cliniques universitaires Saint-Luc- Université Catholique de LouvainNot applicable NCT06897319
  11. Minor: Impact of Keratinized Mucosa Augmentation on Treatment Outcomes of Peri-implant Mucositis Primary completion pushed from Sep 10, 2026 to Dec 10, 2026 Biruni UniversityNot applicable NCT06305000
  12. Minor: Detection of Microplastics · Periodontitis Primary completion pushed from Feb 1, 2027 to Jul 1, 2027 Sigmund Freud PrivatUniversitatNot specified NCT07231198
  13. Minor: Integrated Grief Therapy on Psychological Resilience, Post-Traumatic Growth, Traumatic Stress, and Grief Processes in Earthquake Survivors Primary completion pushed from Aug 1, 2026 to Dec 1, 2026 Sakarya UniversityNot applicable NCT07641270
  14. Minor: Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) · Muscle Invasive Bladder Cancer (EV-309) Trial sites expanded: 29 → 37 locations Astellas Pharma Global Development, Inc.Phase 3 NCT07566156
  15. Minor: NBI-1065845-MDD3026 · Osavampator as an Adjunctive Treatment · Major Depressive Disorder (MDD) Trial sites expanded: 35 → 39 locations Neurocrine BiosciencesPhase 3 NCT06963021
  16. Minor: Denifanstat · Moderate to Severe Acne (AURORA) Trial sites expanded: 28 → 35 locations Sagimet Biosciences Inc.Phase 3 NCT07863193
  17. Minor: NBI-1065845-MDD3025 · Osavampator as an Adjunctive Treatment · Major Depressive Disorder (MDD) Trial sites expanded: 39 → 42 locations Neurocrine BiosciencesPhase 3 NCT06911112
  18. Minor: Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine · Acute Myeloid Leukemia (AML) Trial sites expanded: 36 → 40 locations AbbViePhase 2/3 NCT07581002
  19. Minor: Osavampator as an Adjunctive Treatment · Major Depressive Disorder (MDD) Trial sites expanded: 18 → 30 locations Neurocrine BiosciencesPhase 3 NCT06786624
  20. Minor: Oral Pyridoxal 5'-Phosphate · PNPO Deficiency Trial sites expanded: 7 → 10 locations MedicurePhase 3 NCT04706013
  21. Minor: Tividenofusp Alfa (DNL310) · Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007 Trial sites expanded: 29 → 32 locations Denali Therapeutics Inc.Phase 2/3 NCT06075537
  22. Minor: VER-01 · Chronic Painful Lumbosacral Radiculopathy Trial sites expanded: 40 → 43 locations Vertanical GmbHPhase 3 NCT06956014
  23. Minor: Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn · Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks Trial sites expanded: 0 → 26 locations Phathom Pharmaceuticals, Inc.Phase 3 NCT07752407
  24. Minor: FORTIFI-HN01 · Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC Trial sites expanded: 231 → 242 locations Bicara TherapeuticsPhase 2/3 NCT06788990
  25. Minor: Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination · a KRAS G12C Mutation KRYSTAL-7 Trial sites expanded: 770 → 776 locations Mirati Therapeutics Inc.Phase 2/3 NCT04613596